TW202313592A - 喹啉胺類化合物、其製備方法及其在醫藥上的應用 - Google Patents
喹啉胺類化合物、其製備方法及其在醫藥上的應用 Download PDFInfo
- Publication number
- TW202313592A TW202313592A TW111119883A TW111119883A TW202313592A TW 202313592 A TW202313592 A TW 202313592A TW 111119883 A TW111119883 A TW 111119883A TW 111119883 A TW111119883 A TW 111119883A TW 202313592 A TW202313592 A TW 202313592A
- Authority
- TW
- Taiwan
- Prior art keywords
- general formula
- alkyl
- pharmaceutically acceptable
- acceptable salt
- cycloalkyl
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110606803 | 2021-05-27 | ||
| CN202110606803.1 | 2021-05-27 | ||
| CN202110976020.2 | 2021-08-24 | ||
| CN202110976020 | 2021-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202313592A true TW202313592A (zh) | 2023-04-01 |
Family
ID=84228425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111119883A TW202313592A (zh) | 2021-05-27 | 2022-05-27 | 喹啉胺類化合物、其製備方法及其在醫藥上的應用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240327388A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4349831B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7881616B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240014059A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117222639B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022283404A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024741A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219657A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013972A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202313592A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022247920A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202436295A (zh) * | 2022-11-25 | 2024-09-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹啉胺類化合物的可藥用鹽、晶型及其製備方法 |
| TW202436296A (zh) * | 2022-11-25 | 2024-09-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹啉胺類化合物晶型及其製備方法 |
| CN116854634B (zh) * | 2023-06-27 | 2025-12-09 | 广东药科大学 | 一种选择性ces2抑制剂、其制备方法及其作为药物的用途 |
| IL326865A (en) * | 2023-08-30 | 2026-04-01 | Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd | Compound for regulating activity of microrna-124 |
| WO2025201294A1 (zh) * | 2024-03-26 | 2025-10-02 | 深圳信立泰药业股份有限公司 | 一种吲哚类化合物及其制备方法与miR上调应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5648599A (en) * | 1998-09-11 | 2000-04-03 | Kyorin Pharmaceutical Co. Ltd. | Phosphonic ester derivatives and process for producing the same |
| CN102625804B (zh) | 2009-06-12 | 2015-04-08 | Abivax公司 | 用于治疗aids的化合物 |
| JP2011026251A (ja) * | 2009-07-27 | 2011-02-10 | Kowa Co | 2−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤 |
| WO2012037351A1 (en) | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Compounds |
| CN104109165A (zh) | 2013-04-19 | 2014-10-22 | 四川海思科制药有限公司 | 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用 |
| CA2916623C (en) | 2013-07-05 | 2021-09-14 | Abivax | Bicyclic compounds useful for treating diseases caused by retroviruses |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3059236A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
| WO2017158201A1 (en) | 2016-03-18 | 2017-09-21 | Ratiopharm Gmbh | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts |
| EP3669873A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| CA3168533A1 (en) * | 2020-01-24 | 2021-07-29 | The Trustees Of Princeton University | Heterocyclic compounds and uses thereof |
-
2022
- 2022-05-27 WO PCT/CN2022/095441 patent/WO2022247920A1/zh not_active Ceased
- 2022-05-27 US US18/564,512 patent/US20240327388A1/en active Pending
- 2022-05-27 TW TW111119883A patent/TW202313592A/zh unknown
- 2022-05-27 AU AU2022283404A patent/AU2022283404A1/en active Pending
- 2022-05-27 KR KR1020237043944A patent/KR20240014059A/ko active Pending
- 2022-05-27 EP EP22810644.9A patent/EP4349831B1/en active Active
- 2022-05-27 CN CN202280030768.6A patent/CN117222639B/zh active Active
- 2022-05-27 BR BR112023024741A patent/BR112023024741A2/pt unknown
- 2022-05-27 JP JP2023572661A patent/JP7881616B2/ja active Active
- 2022-05-27 CA CA3219657A patent/CA3219657A1/en active Pending
- 2022-05-27 MX MX2023013972A patent/MX2023013972A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7881616B2 (ja) | 2026-06-29 |
| KR20240014059A (ko) | 2024-01-31 |
| JP2024519993A (ja) | 2024-05-21 |
| WO2022247920A9 (zh) | 2023-01-05 |
| EP4349831A4 (en) | 2024-09-04 |
| CN117222639B (zh) | 2026-07-10 |
| MX2023013972A (es) | 2023-12-11 |
| BR112023024741A2 (pt) | 2024-02-15 |
| CN117222639A (zh) | 2023-12-12 |
| EP4349831A1 (en) | 2024-04-10 |
| WO2022247920A1 (zh) | 2022-12-01 |
| US20240327388A1 (en) | 2024-10-03 |
| AU2022283404A1 (en) | 2023-11-30 |
| EP4349831B1 (en) | 2026-08-19 |
| CA3219657A1 (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022247920A1 (zh) | 喹啉胺类化合物、其制备方法及其在医药上的应用 | |
| WO2023066371A1 (zh) | 含氮的四环化合物、其制备方法及其在医药上的应用 | |
| WO2023072297A1 (zh) | 含氮的四环化合物、其制备方法及其在医药上的应用 | |
| CN117486901A (zh) | 稠合哌啶类化合物、其制备方法及其在医药上的应用 | |
| TW202321263A (zh) | 磺醯胺衍生物、其製備方法及其在醫藥上的應用 | |
| WO2024208305A1 (zh) | 稠合四环类化合物、其制备方法及其在医药上的应用 | |
| CN115916768B (zh) | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 | |
| CN116669736B (zh) | 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用 | |
| CN118339157A (zh) | 氢化吲哚类化合物、其制备方法及其在医药上的应用 | |
| CN115433127A (zh) | 喹啉胺类化合物、其制备方法及其在医药上的应用 | |
| TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
| WO2020011220A1 (zh) | 杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| WO2022166810A1 (zh) | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 | |
| TW202521525A (zh) | 雜芳基化合物、其製備方法及其在醫藥上的應用 | |
| WO2025098445A1 (zh) | Parg抑制剂及其制备方法和用途 | |
| CN113912608B (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 | |
| CN115867552B (zh) | 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| WO2022237890A1 (zh) | 氮杂卓类稠环化合物及其医药用途 | |
| CN114685429A (zh) | 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用 | |
| JP2023536442A (ja) | オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用 | |
| WO2023138657A1 (zh) | 喹啉胺类化合物、其制备方法及其在医药上的应用 | |
| CN115835863B (zh) | 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用 | |
| CN114456173B (zh) | 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用 | |
| EA050466B1 (ru) | Соединение хинолинаминового ряда, способ его получения и его применение в фармацевтике | |
| CA3300208A1 (en) | Heteroaryl compound, preparation method therefor, and use thereof in medicine |